Metabolism of anandamide into eoxamides by 15-lipoxygenase-1 and glutathione transferases

Lipids

Volumn 47, Issue 8, 2012, Pages 781-791

  Forsell, Pontus K A ^a,b   Brunnström, Åsa ^a,b,c   Johannesson, Malin ^a   Claesson, Hans Erik ^a,c  

^a Orexo AB   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

15 Lipoxygenase 1; Anandamide; Arachidonic acid; Endocannabinoid; Glutathione; Inflammation; Pain

Indexed keywords

15 LIPOXYGENASE 1; 2 ARACHIDONOYLGLYCEROL; AMIDE; ANANDAMIDE; CYSTEINE; EOXAMIDE; EPOXIDE; ETHANOLAMIDE; GLUTATHIONE TRANSFERASE; LIPID HYDROPEROXIDE; LIPOXYGENASE; PROSTAGLANDIN; PROSTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME PURIFICATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MASS SPECTROMETRY; METABOLISM; MOLECULE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIGNAL TRANSDUCTION; THROMBOCYTE;

ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONIC ACIDS; CELL LINE, TUMOR; ENDOCANNABINOIDS; GLUTATHIONE TRANSFERASE; GLYCERIDES; HODGKIN DISEASE; HUMANS; LEUKOTRIENE D4; LEUKOTRIENES; LIPOXYGENASE; POLYUNSATURATED ALKAMIDES;

EID: 84864346150     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-012-3684-z     Document Type: Article

References (62)

1. Radmark O (2002) Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat 68-69:211-234 (Pubitemid 35247398)
2. Yoshimoto T, Takahashi Y (2002) Arachidonate 12-lipoxygen-ases. Prostaglandins Other Lipid Mediat 68-69:245-262
3. Kuhn H, Walther M, Kuban R (2002) Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat 68-69:263-290 (Pubitemid 35247401)
4. Lam B (2003) Leukotriene C#inf#4#/inf# synthase. Prostaglandins Leukot Essent Fatty Acids 69(2-3):111-116
5. Claesson H, Dahlen S (1999) Asthma and leukotrienes: antileu-kotrienes as novel anti-asthmatic drugs. J Intern Med 245(3): 205-227 (Pubitemid 29132964)
6. Feltenmark S, Gautam N, Brunnstrom A, Griffiths W, Backman L, Edenius C, Lindbom L, Bjorkholm M, Claesson H-E (2008) Eoxins are proinflammatory arachidonic acid metabolites pro-duced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. PNAS 105(2):680-685. doi:10.1073/pnas.07101 27105 (Pubitemid 351171768)
7. Claesson H-E (2009) On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma. Prostaglandins Other Lipid Mediat 89(3-4): 120-125
8. Claesson H, Griffiths W, Brunnstrom A, Schain F, Andersson E, Feltenmark S, Johnson H, Porwit A, Sjoberg J, Bjorkholm M (2008) Hodgkin Reed-Sternberg cells express 15-lipoxygenase-1 and are putative producers of eoxins in vivo: novel insight into the inflammatory features of classical Hodgkin lymphoma. FEBS J 275(16):4222-4234
9. Lam BK, Austen FK (2000) Leukotriene C4 synthase. A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes. Am J Respir Crit Care Med 161(2):S16-S19 (Pubitemid 30129409)
10. Sjostrom M, Jakobsson PJ, Heimburger M, Palmblad J, Haegg-strom JZ (2001) Human umbilical vein endothelial cells generate leukotriene C4 via microsomal glutathione S-transferase type 2 and express the Cys LT(1) receptor. Eur J Biochem 268(9): 2578-2586 (Pubitemid 32861464)
11. Brunnstrom A, Hamberg M, Griffiths W, Mannervik B, Claesson H (2011) Biosynthesis of 14,15-hepoxilins in human l1236 Hodgkin lymphoma cells and eosinophils. Lipids 46(1):69-79
12. Conrad M, Sandin A, Forster H, Seiler A, Frijhoff J, Dagnell M, Bornkamm GW, Radmark O, van Huijsduijnen RH, Aspenstrom P, Bohmer F, Ostman A (2010) 12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase signaling through oxidation of protein tyrosine phosphatases. PNAS 107(36): 15774-15779. doi:10.1073/pnas.1007909107
13. Zhao J, O'Donnell VB, Balzar S, St. Croix CM, Trudeau JB, Wenzel SE (2011) 15-Lipoxygenase 1 interacts with phosphati-dylethanolamine-binding protein to regulate MAPK signaling in human airway epithelial cells. PNAS, 108(34): 14246-14251. doi:10.1073/pnas.1018075108
14. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LAJ, Perretti M, Rossi AG, Wallace JL (2006) Resolution of inflammation: state of the art, definitions and terms. FASEB J: fj.06-7227com. doi:10.1096/fj.06-7227com
15. Kuhn H, O'Donnell V (2006) Inflammation and immune regu-lation by 12/15-lipoxygenases. Prog Lipid Res 45(4):334-356
16. Gulliksson M, Brunnstrom A, Johannesson M, Backman L, Nilsson G, Harvima I, Dahlen B, Kumlin M, Claesson H (2007) Expression of 15-lipoxygenase type-1 in human mast cells. Biochim Biophys Acta 1771(9):1156-1165 (Pubitemid 47404969)
17. Van Dyke TE, Serhan CN (2003) Resolution of Inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 82(2):82-90. doi:10.1177/154405910308200202 (Pubitemid 41764116)
18. Andersson C, Claesson H-E, Rydell-Tormanen K, Swedmark S, Hallgren A, Erjefalt JS (2008) Mice lacking 12/15-lipoxygenase have attenuated airway allergic inflammation and remodeling. Am J Respir Cell Mol Biol 39(6):648-656. doi:10.1165/rcmb. 2007-0443OC
19. Hajek A, Lindley A, Favoreto S, Carter R, Schleimer R, Ku-perman D (2008) 12/15-Lipoxygenase deficiency protects mice from allergic airways inflammation and increases secretory Ig A levels. J Allergy Clin Immunol 122(3):633-639.e3
20. Liu C, Xu D, Liu L, Schain F, Brunnstrom A, Bjorkholm M, Claesson H-E, Sjoberg J (2009) 15-Lipoxygenase-1 induces expression and release of chemokines in cultured human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 297(1):L196-L203. doi:10.1152/ajplung.00036.2008
21. Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Ta-kahashi H, Okada S, Tateno K, Moriya J, Yokoyama M, Nojima A, Yoshimura M, Egashira K, Aburatani H, Komuro I (2009) Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med 206(7):1565-1574. doi:10.1084/jem.20082596
22. Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Schneckenle-ithner C, Wolbank S, Bartel G, Krieger S, Kalt R, Hantusch B, Keller T, Nagy-Bojarszky K, Huttary N, Raab I, Lackner K, Krautgasser K, Schachner H, Kaserer K, Rezar S, Madlener S, Vonach C, Davidovits A, Nosaka H, Hammerle M, Viola K, Dolznig H, Schreiber M, Nader A, Mikulits W, Gnant M, Hi-rakawa S, Detmar M, Alitalo K, Nijman S, Offner F, Maier T, Steinhilber D, Krupitza G (2011) Lipoxygenase mediates inva-sion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest 121(5):2000-2012
23. Cornicelli J (1998) 15-lipoxygenase inhibitors as anti-athero-sclerosis agents. I Drugs 1(2):206-213
24. Bocan T, Rosebury W, Mueller S, Kuchera S, Welch K, Daugherty A, Cornicelli J (1998) A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit Atherosclerosis 136(2):203-216 (Pubitemid 28133408)
25. Zhao L, Pratico D, Rader D, Funk C (2005) 12/15-Lipoxygenase gene disruption and vitamin E administration diminish athero-sclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat 78(1-4):185-193 (Pubitemid 41636842)
26. Pratico D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, Trojanowski JQ, Lee VM-Y (2004) 12/15-Lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 164(5):1655-1662 (Pubitemid 38529768)
27. Vahsen S, Rakowski K, Ledwig D, Dietze-Schroeder D, Swifka J, Sasson S, Eckel J (2006) Altered GLUT4 translocation in skeletal muscle of 12/15-lipoxygenase knockout mice. Horm Metab Res 38(6):391-396 (Pubitemid 44047961)
28. Xu Z, Li S, Lanting L, Kim Y, Shanmugam N, Reddy M, Nat-arajan R (2006) Relationship between 12/15-lipoxygenase and COX-2 in mesangial cells: potential role in diabetic nephropathy. Kidney Int 69(3):512-519 (Pubitemid 43164443)
29. van Leyen K, Arai K, Jin G, Kenyon V, Gerstner B, Rosenberg P, Holman T, Lo E (2008) Novel lipoxygenase inhibitors as neu-roprotective reagents. J Neurosci Res 86(4):904-909 (Pubitemid 351357770)
30. Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K (1995) Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1254(2):127-134
31. Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, Du Bois RN, Brash AR, Marnett LJ (2002) 15-lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 277(26):23278-23286 (Pubitemid 34952156)
32. Moody J, Kozak K, Ji C, Marnett L (2001) Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry 40(4):861-866 (Pubitemid 32108577)
33. Hampson A, Hill W, Zan-Phillips M, Makriyannis A, Leung E, Eglen R, Bornheim L (1995) Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabi-noid receptor. Biochim Biophys Acta 1259(2):173-179
34. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB (1998) Human platelets and polymorphonuclear leukocytes syn-thesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54(1):180-188 (Pubitemid 28337601)
35. Prusakiewicz J, Turman M, Vila A, Ball H, Al-Mestarihi A, Di Marzo V, Marnett L (2007) Oxidative metabolism of lipoamino acids and vanilloids by lipoxygenases and cyclooxygenases. Arch Biochem Biophys 464(2):260-268 (Pubitemid 47224932)
36. Sugiura T, Waku K (2002) Cannabinoid receptors and their endogenous ligands. J Biochem 132(1):7-12 (Pubitemid 34832264)
37. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Marti BR, Mechou-lam R, Pertwee RG (2002) International union of pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54(2):161-202. doi:10.1124/pr.54.2.161 (Pubitemid 34575709)
38. De Petrocellis L, Di Marzo V (2005) Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) chan-nels. Life Sci 77(14):1651-1666 (Pubitemid 41073659)
39. Turman M, Kingsley P, Rouzer C, Cravatt B, Marnett L (2008) Oxidative metabolism of a fatty acid amide hydrolase-regulated lipid, arachidonoyltaurine. Biochemistry 47(12):3917-3925 (Pubitemid 351431381)
40. Yu M, Ives D, Ramesha CS (1997) Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272(34):21181-21186. doi:10.1074/jbc.272.34.21181 (Pubitemid 27373979)
41. Kozak KR, Rowlinson SW, Marnett LJ (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prosta-glandins by cyclooxygenase-2. J Biol Chem 275(43):33744-33749. doi:10.1074/jbc.M007088200
42. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Wein-ander R, Jakobsson PJ, Marnett LJ (2002) Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277(47):44877-44885 (Pubitemid 36159083)
43. Woodward D, Liang Y, Krauss A (2008) Prostamides (pros-taglandin- ethanolamides) and their pharmacology. Br J Pharmacol 153(3):410-419
44. Rouzer C, Marnett L (2011) Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 111(10):5899-5921
45. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MCG, Ward AM, Lichtman AH, Conti B, Cravatt BF (2011) Endocannabinoid hydrolysis generates brain prostaglan-dins that promote neuroinflammation. Science. doi:10.1126/ science.1209200
46. Dahlstrom M, Forsstrom D, Johannesson M, Huque-Andersson Y, Bjork M, Silfverplatz E, Sanin A, Schaal W, Pelcman B, Forsell PKA (2010) Development of a fluorescent intensity assay amenable for high-throughput screening for determining 15-lipoxygenase activity. J Biomol Screen 15(6):671-679. doi: 10.1177/1087057110373383
47. Johannesson M, Backman L, Claesson H, Forsell P (2010) Cloning, purification and characterization of non-human primate 12/15-lipoxygenases. Prostaglandins Leukot Essent Fatty Acids 82(2-3):121-129
48. Forsell P, Olsson A, Andersson E, Nallan L, Gelb M (2005) Polychlorinated biphenyls induce arachidonic acid release in human platelets in a tamoxifen sensitive manner via activation of group IVA cytosolic phospholipase A2-alpha. Biochem Pharmacol 71(1-2):144-155 (Pubitemid 41713536)
49. Edenius C, Stenke L, Tornhamre S, Heidvall K, Forsberg I, Nasman-Glaser B, Lindgren J (1991) Metabolism ofgranulocyte-derived leukotriene A4 in human platelets and respiratory tissue: transcellular formation of lipoxins and leukotrienes. Adv Exp Med Biol 314:281-288
50. Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7(5):438-455 (Pubitemid 351649182)
51. Chang L, Luo L, Palmer J, Sutton S, Wilson S, Barbier A, Bre-itenbucher J, Chaplan S, Webb M (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148(1):102-113 (Pubitemid 43675605)
52. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V (2006) Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26(51): 13318-13327. doi:10.1523/jneurosci.3326-06. 2006 (Pubitemid 46011642)
53. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH (2010) Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 334(1):182-190. doi:10.1124/ jpet.109.164806
54. Trang T (2007) Inhibition of fatty acid amide hydrolase: a potential treatment for neuropathic pain. J Neurosci 27(13):3364-3365. doi:10.1523/jneurosci.0583-07.2007 (Pubitemid 46515117)
55. Dray A (2008) Neuropathic pain: emerging treatments. Br J Anaesth 101(1):48-58. doi:10.1093/bja/aen107 (Pubitemid 351881912)
56. Edenius C, Heidvall K, Lindgren J (1988) Novel transcellular interaction: conversion of granulocyte-derived leukotriene A4 to cysteinyl-containing leukotrienes by human platelets. Eur J Biochem 178(1):81-86 (Pubitemid 19010190)
57. Lindgren J, Hulting A, Hokfelt T, Dahlen S, Eneroth P, Werner S, Patrono C, Samuelsson B (1985) Evidence for leukotriene for-mation and a neuroendocrine role for leukotriene C4 in rat brain. Adv Prostaglandin Thromboxane Leukot Res 15:561-564
58. Schalling M, Neil A, Terenius L, Lindgren J, Miamoto T, Hokfelt T, Samuelsson B (1986) Leukotriene C4 binding sites in the rat central nervous system. Eur J Pharmacol 122(2):251-257 (Pubitemid 16038039)
59. Wang L, Du C, Lv J, Wei W, Cui Y, Xie X (2011) Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and patho-genesis of experimental autoimmune encephalomyelitis. J Immunol 187(5):2336-2345. doi:10.4049/jimmunol.1100333
60. Rayman N, Lam K, Van Leeuwen J, Mulder A, Budel L, Lowenberg B, Sonneveld P, Delwel R (2007) The expression of the peripheral cannabinoid receptor on cells of the immune sys-tem and non-Hodgkin's lymphomas. Leuk Lymphoma 48(7): 1389-1399 (Pubitemid 47079367)
61. Rayman N, Lam KH, Laman JD, Simons PJ, Lowenberg B, Sonneveld P, Delwel R (2004) Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. J Immunol 172(4):2111-2117 (Pubitemid 38182356)
62. Van Der Stelt M, Van Kuik J, Bari M, Van Zadelhoff G, Leeflang B, Veldink G, Finazzi-Agro A, Vliegenthart J, Maccarrone M (2002) Oxygenated metabolites of anandamide and 2-arachido-noylglycerol: conformational analysis and interaction with can-nabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45(17):3709-3720 (Pubitemid 34856111)